Assenagon Asset Management S.A. Has $498,000 Stock Position in Emergent Biosolutions Inc. $EBS

Assenagon Asset Management S.A. reduced its stake in Emergent Biosolutions Inc. by 81.8% in Q3, now holding 56,455 shares worth $498,000. Other institutional investors, including Vanguard and Cetera, adjusted their positions in EBS. Emergent Biosolutions' stock opened at $12.63, with a market cap of $663.33 million. Analysts have mixed ratings on the stock, with some upgrading it to "strong-buy."

Gilead Sciences to acquire Repare’s RP-3467

Gilead Sciences has agreed to acquire Repare Therapeutics' Polθ ATPase inhibitor, RP-3467, for up to $30 million. The deal includes a $25 million upfront payment and up to $5 million upon technology transfer completion. This acquisition boosts Repare's cash reserves, impacting shareholder payments, estimated at $2.20 per share. Repare's CEO, Steve Forte, highlights the transaction as a significant portfolio move, combining Gilead's oncology expertise with RP-3467's potential in targeting BRCA mutations.

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Inovio Pharmaceuticals Inc. (INO) shares rose 4.65% to $2.25, outperforming competitors like Johnson & Johnson and Pfizer on a strong trading day. This rise ended a four-day losing streak, although the stock remains 24.47% below its 52-week high. Trading volume was significantly below the 50-day average. The NASDAQ and Dow Jones also saw gains.

Repare Therapeutics Inc. (RPTX) stock price rose over 20% to $2.66, reaching a one-year high. The company announced the sale of its polymerase ATPase inhibitor RP-3467 to Gilead Sciences for $30 million

Tonix Pharmaceuticals Holding Corp. releases report on monoclonal antibody TNX-4800 for Lyme disease prevention

Tonix Pharmaceuticals Holding Corp. has released a report on TNX-4800, a monoclonal antibody for Lyme disease prevention. The document highlights the growing prevalence of Lyme disease and the potential of monoclonal antibodies as a preventive treatment. This AI-generated news brief is for informational purposes only and not financial advice. The original content was published by Tonix Pharmaceuticals on December 24, 2025.